Page last updated: 2024-09-19

toxopyrimidine

Description

4-amino-5-hydroxymethyl-2-methylpyrimidine : An aminopyrimidine that is pyrimidine in which the hydrogens at positions 2, 4, and 5 are replaced by methyl, amino, and hydroxymethyl substituents, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID777
CHEMBL ID1233354
CHEBI ID16892
SCHEMBL ID479344
MeSH IDM0058802

Synonyms (65)

Synonym
CHEMBL1233354
(4-amino-2-methylpyrimidin-5-yl)methanol
CHEBI:16892 ,
2-methyl-4-amino-5-hydroxymethylpyrimidine
txp ,
nsc-28247
atoxopyrimidine
ompm
pyrazan
nsc28247
pyramine (thiamine metabolite)
5-pyrimidinemethanol, 4-amino-2-methyl-
NCHEMBIO.2007.13-COMP6 ,
OPREA1_032125 ,
HMH ,
pyramin
C01279 ,
4-amino-2-methyl-5-hydroxymethylpyrimidine
4-amino-5-hydroxymethyl-2-methylpyrimidine
pyramine
hydroxymethylpyrimidine
toxopyrimidine ,
73-67-6
4-amino-2-methyl-5-pyrimidinemethanol
DB02022 ,
EC-000.1414 ,
(4-amino-2-methyl-5-pyrimidinyl)methanol
pyramine (van)
bbv-00026439
5-pyrimidinemethanol, 4-amino-2-methyl- (8ci)(9ci)
pyramin (van)
2-m-4-a-5-hmp
6-amino-5-hydroxymethyl-2-methylpyrimidine
oxymethylpyrimidine
nsc 28247
zinc00895559
STK374214
AKOS002676258
A19113
g62v17j09j ,
unii-g62v17j09j
FT-0647258
5-pyrimidinemethanol,4-amino-2-methyl-
pyramine [van]
toxopyrimidine [mi]
J-501348
DTXSID80223275
4amino-5-hydroxymethyl-2-methylpyrimidine
2-methyl-4-amino-5-hydroxylmethylpyrimidine
VUTBELPREDJDDH-UHFFFAOYSA-N
SCHEMBL479344
mfcd00849239
CS-W006265
4-amino-2-methylpyrimidine-5-methanol
DS-11140
Q27093111
AMY15845
EN300-135390
BBL100129
(4-amino-2-methyl-pyrimidin-5-yl)methanol
SB57336
(4-amino-2-methyl-pyrimidin-5-yl)-methanol
PD008215
2-methyl-4-amino-5-(hydroxymethyl)pyrimidine
Z1198155379

Roles (2)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
aromatic primary alcoholAny primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (12)

toxopyrimidine is involved in 12 pathway(s), involving a total of 52 unique proteins and 224 unique compounds

PathwayProteinsCompounds
Vitamin B1/Thiamine Metabolism819
thiamine salvage IV (yeast)415
thiamine formation from pyrithiamine and oxythiamine (yeast)015
thiamine salvage II011
hydroxymethylpyrimidine salvage16
thiamine diphosphate salvage IV (yeast)015
thiamine salvage IV (yeast)417
base-degraded thiamine salvage36
hydroxymethylpyrimidine salvage67
thiamine formation from pyrithiamine and oxythiamine (yeast)317
thiamine salvage II928
thiamin salvage IV917
base-degraded thiamin salvage16
thiamin formation from pyrithiamine and oxythiamine317
thiamin salvage II011
Thiamin biosynthesis117

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (27.66)18.7374
1990's10 (21.28)18.2507
2000's14 (29.79)29.6817
2010's8 (17.02)24.3611
2020's2 (4.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (95.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]